List of Excipients in Branded Drug FLOVENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	FLOVENT	fluticasone propionate	0173-0602	LACTOSE
GlaxoSmithKline LLC	FLOVENT	fluticasone propionate	0173-0718	NORFLURANE
A-S Medication Solutions	FLOVENT	fluticasone propionate	50090-0910	NORFLURANE
A-S Medication Solutions	FLOVENT	fluticasone propionate	50090-0916	NORFLURANE

FLOVENT Excipient Strategy and Commercial Opportunities in Inhaled Fluticasone Propionate

Last updated: August 2, 2026

Flovent is an inhaled fluticasone propionate corticosteroid marketed in two principal delivery systems: Flovent HFA pressurized metered-dose inhaler and Flovent Diskus dry-powder inhaler. The products use different excipient strategies. Flovent HFA relies on hydrofluoroalkane propellant and ethanol, while Flovent Diskus uses lactose carrier particles containing milk proteins. The strongest commercial opportunities are authorized-generic supply, device-compatible reformulation, lactose-free dry-powder alternatives, and regional substitution following GSK’s withdrawal of the branded U.S. product.

What is Flovent and which formulations remain commercially relevant?

Flovent contains fluticasone propionate, a synthetic inhaled corticosteroid used for maintenance treatment of asthma. It is not a rescue medicine and does not provide immediate relief of acute bronchospasm.

Product	Dosage strengths	Delivery system	Key excipients	U.S. commercial position
Flovent HFA	44, 110, 220 mcg per actuation	Pressurized metered-dose inhaler	HFA-134a, ethanol	Branded U.S. product discontinued; authorized-generic substitution available
Flovent Diskus	50, 100, 250, 500 mcg per blister	Dry-powder inhaler	Lactose monohydrate containing milk proteins	U.S. branded product discontinued
Flixotide	Regional equivalent	HFA inhaler or dry-powder device, depending on market	Market-specific	Remains relevant outside the U.S.

GSK announced the discontinuation of Flovent HFA and Flovent Diskus in the United States at the end of 2023, with commercial availability ending in 2024. GSK cited commercial and operational considerations rather than a safety withdrawal. The company introduced authorized generic versions through Prasco Laboratories [1,2].

What excipients are used in Flovent HFA?

Flovent HFA uses a relatively simple formulation. The active pharmaceutical ingredient is suspended in hydrofluoroalkane propellant, with ethanol used as a cosolvent and formulation aid. The product does not use chlorofluorocarbon propellants.

Component	Functional role	Commercial significance
Fluticasone propionate	Inhaled corticosteroid	Requires low-dose uniformity and suspension stability
HFA-134a, norflurane	Propellant	Determines pressure, plume characteristics, valve compatibility and environmental profile
Ethanol	Cosolvent and formulation aid	Affects drug solubility, particle engineering, suspension behavior and spray performance

The HFA formulation is a suspension rather than a simple molecular solution. Fluticasone propionate has low water solubility and must remain uniformly dispersed during storage and use. Formulation performance depends on particle-size distribution, micronization, sedimentation behavior, valve metering, canister coating, actuator geometry and patient shaking technique.

Why is ethanol important in Flovent HFA?

Ethanol can improve wetting and dispersion of micronized fluticasone propionate. Its concentration must remain within a narrow operating range because changes can affect:

• Suspension stability
• Evaporation during actuation
• Plume temperature
• Droplet size
• Fine-particle dose
• Spray force
• Taste and throat deposition
• Canister and valve compatibility

A reformulator cannot treat ethanol as an interchangeable processing solvent. Any change can alter aerodynamic performance and may require comparative pharmaceutical-performance testing, extractables and leachables assessment, and device equivalence studies.

What excipients are used in Flovent Diskus?

Flovent Diskus uses lactose monohydrate as a carrier excipient. The fluticasone propionate particles are blended with lactose and packaged in individual foil blisters. During inhalation, the patient’s inspiratory flow disperses the powder and separates a respirable fraction from the larger carrier particles.

The lactose is not an inert commercial detail. Its particle-size distribution, crystallinity, moisture content, surface energy and supplier controls can affect dose uniformity and aerosolization.

What are the milk-protein risks of Flovent Diskus?

The lactose used in Flovent Diskus contains trace milk proteins. The U.S. prescribing information warns against use in patients with severe milk-protein allergy [3].

This creates a specific opportunity for lactose-free dry-powder formulations. A competing product that uses an alternative carrier, a carrier-free engineered powder, or a different inhaler architecture could remove the milk-protein warning. That change would not automatically establish clinical or regulatory superiority, but it could support differentiation in patients and institutions that avoid lactose-containing inhalation products.

Potential alternative carriers include:

• Mannitol
• Trehalose
• Leucine
• Amino-acid-based dispersibility enhancers
• Spray-dried composite particles
• Engineered porous particles
• Carrier-free micronized blends

Each alternative introduces new development risks involving hygroscopicity, powder cohesion, dose uniformity, chemical stability and device resistance.

How does the Flovent HFA excipient strategy compare with the Diskus strategy?

Attribute	Flovent HFA	Flovent Diskus
Primary excipient system	HFA-134a plus ethanol	Lactose carrier
Dose delivery driver	Valve, actuator, suspension and plume	Inspiratory flow and powder deaggregation
Main development risk	Suspension stability and device performance	Powder flow, moisture sensitivity and respirable fraction
Patient-use dependency	Shaking and actuator technique	Sufficient inspiratory effort
Milk-protein warning	No lactose-related warning	Yes, due to milk-protein contamination
Sustainability issue	HFA propellant greenhouse-gas impact	Lower propellant burden
Substitution opportunity	Authorized generic or HFA reformulation	Lactose-free or alternative-carrier DPI

The HFA product is easier to position as a direct generic substitute because the reference formulation and device are well established. The Diskus product offers more technical white space but has a higher device and powder-equivalence burden.

What commercial opportunities exist for Flovent excipients?

1. Authorized-generic and generic HFA supply

The most immediate opportunity is supply of fluticasone propionate HFA products using the established HFA-134a and ethanol formulation. The commercial value lies in reliable access, device manufacturing, canister filling and regulatory execution rather than a novel excipient claim.

Key requirements include:

• Consistent micronized fluticasone propionate
• Controlled ethanol content
• Suspension uniformity throughout shelf life
• Metered-dose valve reliability
• Actuator and plume equivalence
• Consistent delivered dose and fine-particle dose
• Supply-chain control for HFA-134a

The U.S. market has already shifted toward authorized-generic and generic supply following GSK’s brand discontinuation. Manufacturers with established inhalation filling capacity have an advantage over companies that only possess the active ingredient.

2. HFA-152a or lower-global-warming-propellant reformulation

HFA-134a has a relatively high global-warming potential compared with newer propellants. The inhalation industry is evaluating HFA-152a and other lower-global-warming alternatives for pressurized inhalers.

A fluticasone propionate inhaler using a next-generation propellant could obtain commercial differentiation through:

• Lower greenhouse-gas impact
• Corporate sustainability procurement
• Future environmental regulation compliance
• Portfolio replacement for legacy HFA products

The technical barriers are substantial. Propellant substitution affects vapor pressure, density, flammability, actuator behavior, formulation stability, valve materials and dose delivery. HFA-152a is flammable, creating manufacturing, transportation and facility-design requirements that do not apply in the same way to HFA-134a.

A propellant change would likely require a new pharmaceutical-development package rather than a simple excipient substitution.

3. Lactose-free dry-powder inhalers

A lactose-free fluticasone propionate DPI could target patients with severe milk-protein allergy and manufacturers seeking a differentiated product. The most credible strategies are carrier-free particles or alternative excipients with established inhalation safety profiles.

Commercial value depends on more than removing lactose. The product must demonstrate:

• Delivered-dose uniformity
• Aerodynamic particle-size distribution
• Robustness across inhalation flow rates
• Moisture resistance
• Device compatibility
• Long-term chemical and physical stability
• Acceptable local tolerability

The product could be positioned against lactose-containing inhaled corticosteroids and against combination products that use lactose carriers.

4. Excipients for improved powder dispersion

Leucine and other surface-active or low-density excipients can improve powder dispersibility and reduce cohesion. Spray-dried particle engineering may permit high drug loading and improved fine-particle performance.

Potential commercial claims include lower dependence on high inspiratory flow, improved dose consistency and improved usability in pediatric or respiratory-limited populations. These claims require clinical and in-use support. They cannot be inferred from laboratory aerosol data alone.

5. Device-excipient integration

Flovent’s commercial value is tied to its delivery device. Inhalation products are combination products in the regulatory sense, and the excipient strategy cannot be separated from the container-closure and device system.

Commercial opportunities include:

• Low-residual-volume actuators
• Dose counters
• Breath-actuated systems
• Improved suspension metering
• Moisture-protective DPI packaging
• Recyclable or lower-material inhalers
• Pediatric spacers and compatible accessories

A device change may create new intellectual-property protection around actuator geometry, valve design, powder loading, dose counting or formulation-device interaction.

When did Flovent lose U.S. exclusivity and what is the generic-entry risk?

Flovent’s principal U.S. market protection has expired. The major commercial issue is no longer whether the original brand can maintain exclusivity. It is whether generic and authorized-generic suppliers can achieve reliable product availability and payer access.

Risk category	Flovent HFA	Flovent Diskus
Composition patent risk	Low relative to historical position	Low relative to historical position
Device-equivalence risk	High	High
Formulation risk	Suspension and propellant compatibility	Powder dispersion and moisture control
Manufacturing risk	Canister filling and valve assembly	Blister production and DPI assembly
Regulatory pathway	ANDA or authorized-generic strategy	ANDA with device and performance requirements
Commercial entry risk	Supply execution and contracting	Device substitution and patient familiarity

Paragraph IV litigation was historically relevant to generic fluticasone propionate inhalers, but current commercial exposure is driven more by product availability, regulatory approvals, device manufacturing and market access than by a live branded Flovent exclusivity barrier. Orange Book listings and FDA patent certifications must be reviewed product by product because HFA and Diskus products have different dosage forms, devices and listing histories [4,5].

What is the FDA regulatory status of Flovent?

Flovent HFA and Flovent Diskus were approved under new drug applications for maintenance treatment of asthma. The products’ U.S. discontinuation was not identified by FDA as a safety or efficacy withdrawal. FDA drug-safety databases distinguish commercial discontinuation from withdrawal for safety or effectiveness reasons [6].

Authorized-generic products may rely on the same approved NDA as the brand product, while independent generic applicants generally must file an ANDA and demonstrate bioequivalence and pharmaceutical equivalence. For inhalers, bioequivalence is assessed through a combination of in vitro performance, pharmacokinetic data where applicable, and clinical endpoint requirements specified by FDA.

What FDA issues matter most for a Flovent substitute?

The principal regulatory issues are:

1. Delivered dose and fine-particle dose.
2. Aerodynamic particle-size distribution.
3. Single-actuation content uniformity.
4. Device performance throughout labeled life.
5. Priming, repriming and storage conditions.
6. Extractables and leachables.
7. Microbial and particulate controls.
8. Human-factors performance for device changes.
9. Labeling for milk-protein allergy where lactose is used.
10. Environmental impact of the propellant.

What patents protect Flovent excipient and delivery systems?

The strongest historical protection for Flovent was associated with the combination of fluticasone propionate, inhalation delivery technology, formulation performance and product-specific device systems. Many early composition and formulation rights have reached expiration or have limited remaining commercial effect in the U.S.

Potentially relevant patent categories include:

• Fluticasone propionate compositions
• Micronized corticosteroid particle production
• HFA suspension formulations
• Ethanol-containing inhaler formulations
• Metering valves and actuators
• Dry-powder carrier blends
• Foil blister packaging
• Dose counters
• Inhaler mechanisms
• Combination inhaled corticosteroid products

Patent strength is generally higher for a differentiated formulation-device combination than for the use of lactose or ethanol alone. Excipients used in conventional concentrations are difficult to protect broadly unless the patent links them to a defined performance result, such as improved fine-particle dose, stability, reduced throat deposition or enhanced dose uniformity.

Which companies are positioned to challenge or replace Flovent?

The competitive field includes:

• Authorized-generic suppliers
• Generic inhaler manufacturers
• Makers of fluticasone propionate HFA products
• Manufacturers of fluticasone propionate-salmeterol combinations
• Suppliers of alternative inhaled corticosteroids
• Device companies with HFA and DPI platforms
• Specialty inhalation companies developing lower-global-warming propellants

Competitive pressure will come from both direct substitution and therapeutic switching. Products containing budesonide, beclomethasone dipropionate, ciclesonide and mometasone furoate compete in the inhaled-corticosteroid market. Combination products containing an inhaled corticosteroid and a long-acting bronchodilator can also capture prescriptions that would otherwise remain with standalone Flovent.

How much revenue exposure does Flovent create?

The discontinuation creates a replacement market rather than a conventional branded-growth opportunity. Revenue exposure is concentrated in:

• U.S. inhaled corticosteroid prescriptions
• Pediatric and low-dose strengths
• Institutional and Medicaid channels
• Authorized-generic contracts
• International fluticasone propionate supply
• Device and component manufacturing
• Propellant transition programs

The most defensible commercial strategy is to separate the market into two segments. HFA substitution is a scale and execution opportunity. DPI reformulation is a differentiated technology opportunity with greater development cost and greater patent potential.

Key Takeaways

• Flovent HFA uses HFA-134a and ethanol with micronized fluticasone propionate.
• Flovent Diskus uses lactose monohydrate containing trace milk proteins.
• The HFA formulation is exposed to propellant-transition opportunities, including lower-global-warming alternatives.
• The Diskus platform creates a commercial opening for lactose-free or carrier-free dry-powder products.
• U.S. brand discontinuation has shifted value toward authorized generics, generic supply and device-compatible substitutes.
• The main barriers are inhaler performance, manufacturing reliability, device equivalence and regulatory execution.
• Excipient patents are strongest when tied to measurable aerosol or stability performance rather than to conventional use of ethanol, lactose or propellant alone.
• Generic entry risk is now primarily commercial and technical, with product-by-product Orange Book and patent-certification analysis still required.

FAQs About Flovent Excipients and Commercial Substitution

Does Flovent HFA contain lactose?

No. Flovent HFA uses HFA-134a and ethanol as inactive ingredients. Lactose is associated with Flovent Diskus, not Flovent HFA [3].

Can patients with milk allergy use Flovent HFA?

The lactose-related milk-protein warning applies to Flovent Diskus. Flovent HFA does not use lactose as an excipient. Product labeling and physician assessment govern individual treatment decisions.

Is HFA-134a a patent opportunity for new Flovent products?

The propellant itself is generally a weak standalone patent target. Stronger protection may arise from a specific propellant-formulation-device combination that improves stability, plume performance, environmental profile or dose delivery.

What is the most commercially attractive Flovent reformulation?

A direct HFA generic has the lowest technical risk and the clearest replacement demand. A lactose-free DPI or lower-global-warming-propellant inhaler has greater differentiation potential but requires more extensive development and regulatory validation.

Does a lactose-free Flovent substitute automatically have a regulatory advantage?

No. Removing lactose may eliminate the milk-protein warning, but the substitute must still demonstrate consistent aerosol performance, stability, safety and efficacy through the applicable FDA pathway.

References

1. GSK plc. (2023). Annual report 2023. https://www.gsk.com
2. Prasco Laboratories. (2024). Fluticasone propionate HFA authorized generic product information. https://www.prasco.com
3. U.S. Food and Drug Administration. (2023). Flovent HFA and Flovent Diskus prescribing information. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
5. U.S. Food and Drug Administration. (2024). Patent listing and certification information for approved drug products. https://www.fda.gov
6. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov